The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Treatment options for pregnant patients with PNH
Yara Aldosari, hematology fellow at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, shares insights into treatment strategies for pregnant patients with paroxysmal nocturnal hemoglobinuria (PNH). While no randomized controlled data on the safety of PNH medications in pregnancy are currently available, she highlights that eculizumab is likely the safest treatment option based on institutional experience and existing literature. Additionally, there is a potential role for ravulizumab, although clinical data remain limited. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There is no clinical control data or randomized control data about the safety of any of the PNH medications in pregnancy. However, based on our experience and also the existing literature experience, eculizumab appears to be the safest option until now, even though the data is still inconclusive, but when we see the outcome, there is no major adverse outcome in those patients...
There is no clinical control data or randomized control data about the safety of any of the PNH medications in pregnancy. However, based on our experience and also the existing literature experience, eculizumab appears to be the safest option until now, even though the data is still inconclusive, but when we see the outcome, there is no major adverse outcome in those patients. Another option is ravulizumab. Ravulizumab is new compared to eculizumab. However, still there is very limited data supporting its use in pregnancy. So still there are case series that are ongoing based on the last ASH reports. So up till now, eculizumab is the pretty safest option for those patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
